S33005

S33005 is a serotonin–norepinephrine reuptake inhibitor (SNRI) that was under development by Servier for the treatment of depression and related disorders. It is structurally related to venlafaxine but has a more complex molecular structure. Venlafaxine appears to be a sigma modulator,[1] but it is not known if S33005 shares this activity.

S33005
Clinical data
Other names(–)-1-(1-dimethylaminomethyl) 5-methoxybenzocyclobutan-1-yl) cyclohexanol
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H27NO2
Molar mass289.419 g·mol−1
3D model (JSmol)

Synthesis

"The 1-cyano-benzocyclobutenes used as starting material are obtained, for example, by subjecting a β-[orthohalogeno-phenyl]-propionitrile to intramolecular condensation in the presence of potassium amide, or by brominating a benzocyclobutene in position 1 with N-bromosuccinimide, followed by exchange of the bromine atom for a cyano group by means of sodium cyanide."[2]

See also

References
  1. Dhir A, Kulkarni SK (June 2007). "Involvement of sigma-1 receptor modulation in the antidepressant action of venlafaxine". Neuroscience Letters. 420 (3): 204–8. doi:10.1016/j.neulet.2007.04.055. PMID 17532136. S2CID 25971336.
  2. U.S. Patent 3,622,614
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.